Read more
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans.
Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
List of contents
Basic Biology of Angiogenesis.- Vascular Endothelial Growth Factor Family and Its Receptors.- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors.- The Role of Integrins in Tumor Angiogenesis.- Tumor Endothelial Cell Abnormalities.- The Extracellular Matrix and VEGF Processing.- Endothelial Precursor Cells.- Role of Pericytes in Angiogenesis.- Newer Vascular Targets.- Chemokines in Angiogenesis.- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis.- Imaging Angiogenesis.- Tumor Blood Vessels.- Lymphatic System in the Pathology of Cancer.- Translational Research in Tumor Angiogenesis.- VEGF in the Adult.- Normalization of Tumor Vasculature and Microenvironment.- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man.- Small-Molecule Vascular Disrupting Agents in Cancer Therapy.- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents.- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside.- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications.- Antiangiogenic Therapy in the Clinical Trial Results and Future Directions.- Angiogenesis and Angiogenesis Inhibition in Sarcomas.- Antiangiogenesis Agents in Colorectal Cancer.- Antiangiogenic Therapy for Primary CNS Tumors.- Angiogenesis Inhibitors for the Treatment of Lung Cancer.- Antiangiogenic Therapy of Renal Cell Carcinoma.- Antiangiogenesis Therapies in Gynecologic Malignancies.- Antiangiogenic Agents in Myeloid Malignancies.- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors.- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis.- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials.- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.
Summary
Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer.
Additional text
From the reviews of the second edition:
"This is a second edition of a well-accepted text on angiogenesis and antiangiogenic agents, particularly on their use in cancer therapy. In addition to the editors, a large number of outstanding investigators have contributed to this book. … This edition is highly recommended to all of those involved in research or the clinical practice of oncology." (Julian L. Ambrus and Clara M. Ambrus, The Journal of Medicine, March, 2008)
Report
From the reviews of the second edition:
"This is a second edition of a well-accepted text on angiogenesis and antiangiogenic agents, particularly on their use in cancer therapy. In addition to the editors, a large number of outstanding investigators have contributed to this book. ... This edition is highly recommended to all of those involved in research or the clinical practice of oncology." (Julian L. Ambrus and Clara M. Ambrus, The Journal of Medicine, March, 2008)
